Blocking the SIRPα/CD47 axis could not only activate adaptive anti-tumor immune responses by promoting antigen cross-presentation by APCs, but also could activate innate immune responses by enhancing the cancer cell clearance by macrophages and DCs [84,88]. Here, SIRPA is linked to neoplasm.